A new nanocarrier-based cancer vaccine used for the treatment of an aggressive and lethal form of skin cancer has been tested on mice, showing promising results.
Researchers have created a new vaccine for the treatment of late-stage metastatic melanoma, an aggressive skin cancer that can resist conventional treatments because it exists in an ecosystem that suppresses the body’s immune response.
This immunosuppressive tumor microenvironment prevents therapies from effectively targeting and eliminating cancer cells. While other cancer interventions, such as targeted therapies and existing immunotherapeutics, have shown some efficacy with melanoma, this environment can cause immune-related adverse effects and rapid tumor relapse, the return of cancer after a…